Coronavirus Clinical Trial
Official title:
Community Partnered Intervention to Increase COVID-19 Vaccine Uptake in Low Income Underresourced African Americans and Latinx Public Housing Residents
Verified date | February 2024 |
Source | Charles Drew University of Medicine and Science |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This proposal seeks to enhance uptake and completion of COVID-19 vaccination among African American and Latinx public housing residents in South Los Angeles. Given the multiple disparities experienced by public housing residents, the investigators will utilize a theoretically-based, multidisciplinary and culturally tailored intervention to provide education at multiple levels and implement innovate strategies to engage this population in the uptake of COVID-19 vaccination.
Status | Completed |
Enrollment | 462 |
Est. completion date | April 1, 2024 |
Est. primary completion date | November 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Aim 2: Inclusion Criteria: - identify as Latinx or African American - age 18 or older - reside in one of the six collaborating public housing area - Speak either English or Spanish Exclusion Criteria: - Not a resident at one of the collaborating public housing areas - Does not self-identify as African American or Latinx - Age 17 and younger - Unable to speak either English or Spanish Aim 3: Inclusion Criteria: - identify as Latinx or African American - age 18 or older - reside in one of the six collaborating public housing area - Speak either English or Spanish - Report vaccine hesitancy Exclusion Criteria: - Not a resident at one of the collaborating public housing areas - Does not self-identify as African American or Latinx - Age 17 and younger - Unable to speak either English or Spanish - Received all recommended vaccines for COVID-19 - No reporting of vaccine hesitancy |
Country | Name | City | State |
---|---|---|---|
United States | Charles R. Drew University of Medicine & Science | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Charles Drew University of Medicine and Science |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence of vaccination uptake for COVID-19, influenza, and pneumonia using Vaccination History Self Report | 1. By comparison of pre-, post- intervention, and 9- and 18-months follow-up data, we anticipate the following compared to baseline: a 40% change in completion of COVID-19 vaccination series | Intervention: 4 months; Follow-up Point: 3 months post-intervention | |
Secondary | Percentage of Participants Achieving Decreased Vaccine Hesitancy Levels of COVID-19 vaccine Using the NIH Toolbox Surveys on COVID-19 | 1. By comparison of pre-, post- intervention, and 3-months follow-up data, we anticipate the following compared to baseline: a 40% change in hesitancy toward COVID-19 vaccination. | Intervention: 4 months; Follow-up Point: 3 months post-intervention | |
Secondary | Percentage of Participants Achieving Increased Level of Behavior Change toward COVID-19 Vaccination Using the NIH Toolbox Surveys on COVID-19 | 2. By comparison of pre-, post- intervention, and 3-months follow-up data, we anticipate the following compared to baseline: a 40% change in their behavior stage of change toward COVID-19 vaccination | Intervention: 4 months; Follow-up Point: 3 months post-intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05065827 -
Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
|
||
Recruiting |
NCT05359770 -
Association of Inspiratory Muscle Training With HD-tDCS for Assistance to Patients With Long Covid-19
|
N/A | |
Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
Not yet recruiting |
NCT06025812 -
Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
|
N/A | |
Recruiting |
NCT05289115 -
Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS
|
N/A | |
Completed |
NCT04953078 -
A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19
|
Phase 1 | |
Not yet recruiting |
NCT05868239 -
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
|
N/A | |
Completed |
NCT04818164 -
Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04690413 -
NOWDx Test for the Detection of Antibodies to COVID-19
|
N/A | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Completed |
NCT04572399 -
UVA Light Device to Treat COVID-19
|
N/A | |
Recruiting |
NCT04610567 -
Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04772170 -
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
|
||
Recruiting |
NCT04581954 -
Inflammatory Signal Inhibitors for COVID-19 (MATIS)
|
Phase 1/Phase 2 | |
Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
Enrolling by invitation |
NCT04484025 -
SPI-1005 Treatment in Moderate COVID-19 Patients
|
Phase 2 | |
Completed |
NCT05572840 -
Wear Your Mask, Wash Your Hands, Don't Get COVID-19
|
N/A | |
Withdrawn |
NCT04838847 -
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
|
Phase 3 | |
Completed |
NCT04556149 -
imPulseā¢ Una Full-spectrum, Over Clothing E-stethoscope
|
||
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 |